aTYR PHARMA INC — Form 10-Q
Filed August 7, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Brandon Yaras promoted to Chief Financial Officer effective October 1, 2026, with annual base salary of $350,000, target bonus of 40% of base ($140,000), and 410,000 stock option grant vesting over 4 years. Prior role was Vice President, Finance. Exercise price to be set at grant-date NASDAQ closing price. Reporting to CEO Sanjay S. Shukla.
Why this rating
Internal promotion of known finance executive. Modest compensation ($350K base) is <0.08% of $463.8M market cap; 410K options are material but vesting over 4 years is standard. No external hire cost, operational continuity preserved.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.